HighTower Advisors’s Aimmune Therapeutics AIMT Stock Holding History

HighTower Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,461	Closed	-$395K	–	3058
2020 Q3	$395K	Sell	11,461 -6,103	-35%	-$130K	﹤0.01%	1686
2020 Q2	$294K	Buy	17,564 +4,585	+35%	+$77.8K	﹤0.01%	1755
2020 Q1	$186K	Buy	12,979 +6,969	+116%	+$178K	﹤0.01%	1814
2019 Q4	$203K	Buy	+6,010	New	+$168K	﹤0.01%	1967

HighTower Advisors's AIMT Position: Q4 2020 in Review

HighTower Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 11,461 shares — an estimated $395K sold.

HighTower Advisors first reported a position in AIMT in Q4 2019 and held it in 4 quarters. The position peaked at $395K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

HighTower Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
HighTower Advisors sold 11,461 Aimmune Therapeutics shares in Q4 2020, an estimated $395K.
HighTower Advisors first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 4 quarters.
HighTower Advisors's Aimmune Therapeutics position peaked at $395K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on HighTower Advisors's 13F filing for Q4 2020, filed 10 Feb 2021.